MK-3682B

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Digestive System DiseasesFlaviviridae InfectionsHepatitisHepatitis CHepatitis, Viral, HumanLiver DiseasesRNA Virus InfectionsVirus Diseases

Phase 1

Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)

CompletedNCT02661126

Merck Sharp & Dohme LLCHepatitis C

Start: 2016-01-19End: 2016-08-26Updated: 2019-01-09

Phase 2

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

CompletedNCT02332720

Merck Sharp & Dohme LLCHepatitis C

Start: 2015-01-28End: 2017-05-03Updated: 2019-07-30

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

TerminatedNCT02613403

Merck Sharp & Dohme LLCDigestive System Diseases, Flaviviridae Infections, Hepatitis +5

Start: 2015-12-10End: 2017-03-27Updated: 2024-05-22

Related Papers

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

2017-08-1018 citations

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

2017-08-1012 citations